BACKGROUND: ADAM12-S is a pregnancy-associated insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5 protease present in human gestational serum. Recently, maternal serum levels of ADAM12-S were found to be markedly reduced during the first trimester of pregnancies with a Down syndrome (DS) fetus. On the basis of this finding, it was suggested that ADAM12-S might be a useful maternal serum marker of fetal chromosomal disease. OBJECTIVE: Retrospective examination of the use of ADAM12-S as a marker for fetal trisomy 18. METHOD: Serum samples were obtained from ten women during the first semester of their pregnancies with fetuses that had trisomy 18. An ELISA was used to determine the levels of ADAM12 in maternal serum. Results were compared to ADAM12-S levels, previously measured in the serum of 170 women carrying normal pregnancies during the first trimester. RESULTS: In all cases, the ADAM12-S concentration in maternal serum samples was lower in trisomy 18 pregnancies than in normal pregnancies, with a median multiple of the median (MoM) of 0.28 (p < 0.001) CONCLUSION: A reduced concentration of ADAM12-S in maternal serum is a promising marker for foetal trisomy 18, as well as for DS. Copyright (c) 2005 John Wiley & Sons, Ltd.
BACKGROUND:ADAM12-S is a pregnancy-associated insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5 protease present in human gestational serum. Recently, maternal serum levels of ADAM12-S were found to be markedly reduced during the first trimester of pregnancies with a Down syndrome (DS) fetus. On the basis of this finding, it was suggested that ADAM12-S might be a useful maternal serum marker of fetal chromosomal disease. OBJECTIVE: Retrospective examination of the use of ADAM12-S as a marker for fetal trisomy 18. METHOD: Serum samples were obtained from ten women during the first semester of their pregnancies with fetuses that had trisomy 18. An ELISA was used to determine the levels of ADAM12 in maternal serum. Results were compared to ADAM12-S levels, previously measured in the serum of 170 women carrying normal pregnancies during the first trimester. RESULTS: In all cases, the ADAM12-S concentration in maternal serum samples was lower in trisomy 18 pregnancies than in normal pregnancies, with a median multiple of the median (MoM) of 0.28 (p < 0.001) CONCLUSION: A reduced concentration of ADAM12-S in maternal serum is a promising marker for foetal trisomy 18, as well as for DS. Copyright (c) 2005 John Wiley & Sons, Ltd.
Authors: Mary E Rausch; Lynn Beer; Mary D Sammel; Peter Takacs; Karine Chung; Alka Shaunik; David Speicher; Kurt T Barnhart Journal: Fertil Steril Date: 2011-02-01 Impact factor: 7.329
Authors: N Rocks; C Estrella; G Paulissen; F Quesada-Calvo; C Gilles; M M Guéders; C Crahay; J-M Foidart; P Gosset; A Noel; D D Cataldo Journal: Cell Prolif Date: 2008-12 Impact factor: 6.831
Authors: Winston Koh; Wenying Pan; Charles Gawad; H Christina Fan; Geoffrey A Kerchner; Tony Wyss-Coray; Yair J Blumenfeld; Yasser Y El-Sayed; Stephen R Quake Journal: Proc Natl Acad Sci U S A Date: 2014-05-05 Impact factor: 11.205
Authors: Sabine Gack; Alexander Marmé; Frederik Marmé; Gunnar Wrobel; Birgitta Vonderstrass; Gunther Bastert; Peter Lichter; Peter Angel; Marina Schorpp-Kistner Journal: J Mol Med (Berl) Date: 2005-10-25 Impact factor: 4.599
Authors: Maria A Nieves-Colón; Keyla M Badillo Rivera; Karla Sandoval; Vanessa Villanueva Dávalos; Luis E Enriquez Lencinas; Javier Mendoza-Revilla; Kaustubh Adhikari; Ram González-Buenfil; Jessica W Chen; Elisa T Zhang; Alexandra Sockell; Patricia Ortiz-Tello; Gloria Malena Hurtado; Ramiro Condori Salas; Ricardo Cebrecos; José C Manzaneda Choque; Franz P Manzaneda Choque; Germán P Yábar Pilco; Erin Rawls; Celeste Eng; Scott Huntsman; Esteban Burchard; Andrés Ruiz-Linares; Rolando González-José; Gabriel Bedoya; Francisco Rothhammer; Maria Cátira Bortolini; Giovanni Poletti; Carla Gallo; Carlos D Bustamante; Julie C Baker; Christopher R Gignoux; Genevieve L Wojcik; Andrés Moreno-Estrada Journal: Am J Hum Genet Date: 2022-05-18 Impact factor: 11.043
Authors: Sanne Ten Hoorn; Cynthia Waasdorp; Martijn G H van Oijen; Helene Damhofer; Anne Trinh; Lan Zhao; Lisanne J H Smits; Sanne Bootsma; Gabi W van Pelt; Wilma E Mesker; Linda Mol; Kaitlyn K H Goey; Miriam Koopman; Jan Paul Medema; Jurriaan B Tuynman; Inti Zlobec; Cornelis J A Punt; Louis Vermeulen; Maarten F Bijlsma Journal: BMC Cancer Date: 2022-04-12 Impact factor: 4.638
Authors: Anjali K Nath; Michael Krauthammer; Puyao Li; Eugene Davidov; Lucas C Butler; Joshua Copel; Mikko Katajamaa; Matej Oresic; Irina Buhimschi; Catalin Buhimschi; Michael Snyder; Joseph A Madri Journal: PLoS One Date: 2009-01-19 Impact factor: 3.240